Contact
searchSearch
HMP Global

Atopic Dermatitis Topic Center

Featured Article

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Maria Asimopoulos
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
Headshot of Shawn Kwatra, MD, Johns Hopkins Itch Center, on a blue background underneath the PopHealth Perspectives logo.
Videos
Topical JAK Inhibitor Reduces Itch in Patients With Atopic Dermatitis
09/30/2022
Maria Asimopoulos
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, shares findings from a recent analysis of two phase 3 trials which investigated the efficacy and safety of a Janus kinase inhibitor for patients with moderate to severe atopic...
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, shares findings from a recent analysis of two phase 3 trials which investigated the efficacy and safety of a Janus kinase inhibitor for patients with moderate to severe atopic...
Shawn Kwatra, MD, FAAD,...
09/30/2022
First Report Managed Care
Headshot of Shawn Kwatra, MD, Johns Hopkins Itch Center, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Increased Market Competition May Impact Patients With Atopic Dermatitis
09/13/2022
Maria Asimopoulos
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, describes how the atopic dermatitis treatment paradigm has been changing amid increased market competition, as well as where the future of care may be headed.
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, describes how the atopic dermatitis treatment paradigm has been changing amid increased market competition, as well as where the future of care may be headed.
Shawn Kwatra, MD, FAAD,...
09/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
Headshot of Shawn Kwatra, MD, Johns Hopkins Itch Center, on a blue background underneath the PopHealth Perspectives logo.
Videos
Reviewing Unmet Need, Clinical Priorities for Patients With Atopic Dermatitis
08/31/2022
Maria Asimopoulos
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, identifies unmet need for patients with atopic dermatitis and shares what factors clinicians and patients prioritize when deciding on a treatment option. 
Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, identifies unmet need for patients with atopic dermatitis and shares what factors clinicians and patients prioritize when deciding on a treatment option. 
Shawn Kwatra, MD, FAAD,...
08/31/2022
First Report Managed Care

Newsfeed

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
Correlation Between Atopic Dermatitis, Neuropsychiatric Comorbidities in Pediatric Populations
08/26/2022
Edan Stanley
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
Acupuncture Might Reduce Itching in Patients With Atopic Dermatitis
07/29/2022
Maria Asimopoulos
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
JAK1 Inhibitor Improves Atopic Dermatitis Symptoms, Even in Nonresponders
07/22/2022
Jolynn Tumolo
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care
Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
News
Differences in OUD Treatment Coverage Across Medicaid Managed Care Plans From 2015 to 2019
05/26/2026
Rebecca Amrick
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid coverage of opioid use disorder (OUD) increased while plans covering treatment services decreased, raising concerns about substance use care plans and treating patients with addiction.
From 2015 to 2019, Medicaid...
05/26/2026
First Report Managed Care
News
Linvoseltamab Demonstrates Lower Care Costs than Teclistamab and Elranatamab for TCE RRMM
05/26/2026
Rebecca Amrick
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower and comparable care costs compared to teclistamab and elranatamab, appearing as a possible lower-cost alternative for treating patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma...
Linvoseltamab demonstrates lower...
05/26/2026
First Report Managed Care
News
Comorbidities Increase Clinical and Economic Burden for Patients With Chronic Kidney Disease
05/22/2026
Rebecca Amrick
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden of chronic kidney disease (CKD) is increased when combined with comorbidities such as type 2 diabetes and heart failure, highlighting the need for improved policies and procedures to optimize disease...
The clinical and economic burden...
05/22/2026
First Report Managed Care
News
Pembrolizumab Plus Chemotherapy Improves Survival in mNSCLC at Higher Cost
05/22/2026
Rebecca Amrick
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy demonstrates more clinical efficiency in treating patients with metastatic non–small cell lung cancer (mNSCLC), but prolonged survival leads to higher overall health care costs.
Pembrolizumab plus chemotherapy...
05/22/2026
First Report Managed Care
Behind the Bill
Congress Targets Enforcement Gaps in the No Surprises Act
05/22/2026
Hannah Musick
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to strengthen enforcement of the No Surprises Act amid growing concerns that some health plans are failing to comply with binding payment decisions in the federal dispute resolution process.
A bipartisan bill aims to...
05/22/2026
First Report Managed Care
News
Asciminib Shows Durable Frontline Benefit in Newly Diagnosed CML
05/20/2026
Hannah Musick
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib demonstrated higher major molecular response rates and fewer treatment discontinuations due to adverse events compared with imatinib and second-generation tyrosine kinase inhibitors in newly diagnosed chronic myeloid...
At 96 weeks, asciminib...
05/20/2026
First Report Managed Care
News
The Effect of Nephologist Affiliation on PD Utilization for Patients With ESKD
05/20/2026
Rebecca Amrick
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that physician-facility alignment influenced treatment for patients with end-stage kidney disease (ESKD) and had a higher likelihood of promoting home-based therapies such as peritoneal dialysis (PD).
A retrospective study found that...
05/20/2026
First Report Managed Care
News
Ponatinib Demonstrates Greater Clinical Benefit Than Imatinib but With Significantly Higher Care Costs
05/20/2026
Rebecca Amrick
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor (TKI) ponatinib has demonstrated moderately better patient outcomes than imatinib, but its higher costs may complicate treatment decision-making for patients, payers, and providers when it comes to managing...
The tyrosine kinase inhibitor...
05/20/2026
First Report Managed Care
News
Severe Alcohol-Associated Hepatitis Raises Health Care Costs Across Multiple Care Settings
05/18/2026
Rebecca Amrick
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for alcohol-associated hepatitis (AH) greatly raises health care costs across outpatient, emergency department (ED), and inpatient settings, reflecting the economic impact of AH severity and its comorbidities.
Immediate care for...
05/18/2026
First Report Managed Care

Recent Content

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Maria Asimopoulos
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use